Heart Test Ownership
| HSCS Stock | USD 2.96 0.05 1.72% |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Heart |
Heart Stock Ownership Analysis
The company has price-to-book (P/B) ratio of 1.74. Some equities with similar Price to Book (P/B) outperform the market in the long run. Heart Test Laboratories recorded a loss per share of 7.61. The entity had not issued any dividends in recent years. The firm had 1:100 split on the 17th of May 2024. Heart Test Laboratories, Inc., a medical technology company, provides cardiovascular diagnostic devices. The company was incorporated in 2007 and is headquartered in Southlake, Texas. Heart Test operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 12 people. To learn more about Heart Test Laboratories call Andrew Simpson at 682-237-7781 or check out https://heartsciences.com.Besides selling stocks to institutional investors, Heart Test also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Heart Test's stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Heart Test's strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Heart Test Quarterly Liabilities And Stockholders Equity |
|
About 9.0% of Heart Test Laboratories are currently held by insiders. Unlike Heart Test's institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Heart Test's private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Heart Test's insider trades
Heart Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Heart Test is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Heart Test Laboratories backward and forwards among themselves. Heart Test's institutional investor refers to the entity that pools money to purchase Heart Test's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Ubs Group Ag | 2024-12-31 | 1.3 K | Oliver Lagore Vanvalin Investment Group | 2024-09-30 | 305 | Tower Research Capital Llc | 2024-12-31 | 100.0 | Bank Of America Corp | 2024-12-31 | 8.0 | Morgan Stanley - Brokerage Accounts | 2024-09-30 | 0.0 | Jpmorgan Chase & Co | 2024-12-31 | 0.0 | Cultivar Capital Inc | 2024-09-30 | 0.0 | Hrt Financial Llc | 2024-12-31 | 0.0 |
Heart Test Laboratories Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Heart Test insiders, such as employees or executives, is commonly permitted as long as it does not rely on Heart Test's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Heart Test insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Mark Hilz over a week ago Discretionary transaction by Mark Hilz of tradable shares of Heart Test subject to Rule 16b-3 | ||
Andrew Simpson over a month ago Disposition of 23216 shares by Andrew Simpson of Heart Test at 6.59 subject to Rule 16b-3 | ||
Andrew Simpson over two months ago Acquisition by Andrew Simpson of 45000 shares of Heart Test at 3.33 subject to Rule 16b-3 | ||
Andrew Simpson over six months ago Acquisition by Andrew Simpson of tradable shares of Heart Test subject to Rule 16b-3 | ||
Mark Hilz over six months ago Disposition of 3788 shares by Mark Hilz of Heart Test at 12.21 subject to Rule 16b-3 | ||
Bent Bruce over a year ago Acquisition by Bent Bruce of 50000 shares of Heart Test subject to Rule 16b-3 |
Heart Test Outstanding Bonds
Heart Test issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Heart Test Laboratories uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Heart bonds can be classified according to their maturity, which is the date when Heart Test Laboratories has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 4875 Corp BondUS55336VAJ98 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View | |
| PEAK 525 15 DEC 32 Corp BondUS42250PAE34 | View |
Heart Test Corporate Filings
8K | 21st of March 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
10Q | 13th of March 2025 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
| 11th of March 2025 Other Reports | ViewVerify | |
| 10th of March 2025 Other Reports | ViewVerify |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Heart Stock Analysis
When running Heart Test's price analysis, check to measure Heart Test's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Heart Test is operating at the current time. Most of Heart Test's value examination focuses on studying past and present price action to predict the probability of Heart Test's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Heart Test's price. Additionally, you may evaluate how the addition of Heart Test to your portfolios can decrease your overall portfolio volatility.